Qualitative data from these studies suggest a clinical ly significant effect of CCH and IFNα-2b injection therapy to decrease penile curvature and conserve penile length .
Verapamil and HA performed well in single-arm or case-control studies .
Studies of penile traction and vacuum devices in patients with PD demonstrated some benefits in terms of curvature and penile length but only in small , underpowered , nonr and omised studies .
Studies of onabotulinum toxin A injections or thiocolchicine showed significant improvements in penile curvature , but only in studies of single-arm or case-control design .
CONCLUSIONS CCH and IFNα-2b injected into stable PD plaques can decrease penile curvature ; CCH can also improve penile length .
However , based on available data , strong conclusions can not be drawn for other treatments , including calcium channel blockers , HA , or mechanical therapies .
PATIENT SUMMARY Our systematic review of injection therapies provides evidence for improvements in penile curvature for patients with Peyronie 's disease .
No robust evidence is available to support the use of other local treatments including calcium channel blockers , hyaluronic acid , or mechanical therapies
CONTEXT Conservative therapies for Peyronie 's disease ( PD ) aim to treat early-stage disease by improving clinical outcomes such as penile curvature , penile length erectile dysfunction , and pain .
OBJECTIVE To summarise the available evidence regarding injection and mechanical therapies for PD treatment .
Intralesional verapamil prevents the progression of Peyronie's disease.
OBJECTIVES To define the impact of intralesional verapamil injection therapy on  penile deformity in men with Peyronie 's disease . METHODS Patients underwent a total of 6 intralesional injections of verapamil .  Penile deformity was assessed at baseline and 3 months after the last intralesional injection of verapamil during penile erection after the administration of intracavernosal medication . Measurement was recorded using a goniometer at maximum penile rigidity . Endpoints included change in magnitude of curvature , stretched penile length , penetration ability , and resolution of pain . RESULTS Ninety-four consecutive patients met all inclusion criteria . Mean ( + /- st and ard deviation ) patient age and duration of Peyronie 's disease at time of baseline deformity assessment were 44 + /- 18 years and 5.2 + /- 2.7 months , respectively . At baseline 86 % had dorsal and 14 % lateral curvature . The mean curvature and stretched flaccid length were 50 degrees + /- 28 degrees and 12.6 + /- 3.1 cm , respectively . At the follow-up evaluation , patients were 5.2 + /- 1.8 months after their last ILV injection and were 11.7 + /- 4.2 months after the onset of Peyronie 's disease . Eighteen percent of patients had improvement of curvature , 60 % were unchanged , and 22 % worsened . Pain resolved in 100 % of patients . CONCLUSIONS In response to intralesional verapamil , a minority of men experienced improvement in penile deformity ; however , the majority of patients had stabilization of their deformity . This information may permit clinicians to give realistic expectations to patients considering intralesional verapamil therapy
Qualitative data from these studies suggest a clinical ly significant effect of CCH and IFNα-2b injection therapy to decrease penile curvature and conserve penile length .
Verapamil and HA performed well in single-arm or case-control studies .
Studies of penile traction and vacuum devices in patients with PD demonstrated some benefits in terms of curvature and penile length but only in small , underpowered , nonr and omised studies .
Studies of onabotulinum toxin A injections or thiocolchicine showed significant improvements in penile curvature , but only in studies of single-arm or case-control design .
CONCLUSIONS CCH and IFNα-2b injected into stable PD plaques can decrease penile curvature ; CCH can also improve penile length .
However , based on available data , strong conclusions can not be drawn for other treatments , including calcium channel blockers , HA , or mechanical therapies .
PATIENT SUMMARY Our systematic review of injection therapies provides evidence for improvements in penile curvature for patients with Peyronie 's disease .
No robust evidence is available to support the use of other local treatments including calcium channel blockers , hyaluronic acid , or mechanical therapies
CONTEXT Conservative therapies for Peyronie 's disease ( PD ) aim to treat early-stage disease by improving clinical outcomes such as penile curvature , penile length erectile dysfunction , and pain .
OBJECTIVE To summarise the available evidence regarding injection and mechanical therapies for PD treatment .